A Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of Staccato Granisetron (AZ-010) for the Acute Treatment of Moderate to Severe Cyclic Vomiting Syndrome
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Cyclic Vomiting Syndrome
- Sponsor
- Alexza Pharmaceuticals, Inc.
- Enrollment
- 150
- Locations
- 18
- Primary Endpoint
- The Number of Vomiting/Retching Events Reported by Study Participants Following Treatment/Dosing During the Home Treament Period.
- Status
- Completed
- Last Updated
- 10 months ago
Overview
Brief Summary
This is a multicenter, randomized, double-blind, parallel group, placebo-controlled, efficacy and safety study of adult outpatients diagnosed with CVS and experiencing recurring episodes of stereotypical vomiting.
Detailed Description
A Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of Staccato Granisetron (AZ-010) for the Acute Treatment of Moderate to Severe Cyclic Vomiting Syndrome
Investigators
Eligibility Criteria
Inclusion Criteria
- •Adult males and females between 18 and 60 years of age, inclusive at the time of signing the informed consent document.
- •Diagnosis of cyclic vomiting syndrome (CVS) using the Rome IV diagnostic criteria.
- •Otherwise healthy, as determined by the responsible physician, based on a medical evaluation including history, physical examination, vital signs, electrocardiograms (ECGs) and laboratory tests assessed at the screening visit
- •Negative urine tests for selected drugs of abuse and alcohol breath test at Screening.
Exclusion Criteria
- •Any significant medical or psychiatric condition that could, in the Investigator's opinion, compromise the subject's safety or interfere with the completion of this protocol.
- •Any condition, including the presence of laboratory abnormalities or pulmonary condition, which according to the Investigator places the subject at unacceptable risk if he/she were to participate in the study.
- •A diagnosis of any gastrointestinal disorder other than CVS that in the judgement of the Investigator could compromise the subject's safety or interfere with the interpretation of safety or efficacy data.
Outcomes
Primary Outcomes
The Number of Vomiting/Retching Events Reported by Study Participants Following Treatment/Dosing During the Home Treament Period.
Time Frame: Within the following timepoints: 30, 60, 90 and 120-minutes post-dose.
The primary efficacy endpoint for this study was the number vomiting/retching events in the two hours following initial treatment. Patients recorded the number of vomiting and retching events that they experienced which occurred 2 hours post dose. Observations occurred at 4 time points: 30 minutes post-dose, 1 hour post-dose, 90 minutes post-dose, and 2 hours post-dose. While each treatment group contained 47-49 patients, only 22-35 patients per treatment group (\~45-70%) recorded vomiting/retching events at any given time point. Safety and tolerability of AZ-010 was assessed by evaluating adverse events, vital signs, 12-lead ECG, clinical laboratory results, and physical examination. Clinically significant deteriorations in physical examination findings (in the opinion of the investigator) are captured and summarized as adverse events.
Secondary Outcomes
- Anxiety/Panic Visual Analog Scale (VAS) Score(24 hours after treatment dose)
- Prior Episode Questionnaire(24 hours after each dose)
- Rescue Medication Use Within 1 Day of Dose(24 hours post dose)
- Health Care Provider Visits; Visit to Urgent Care, Emergency Department, or Physician's Office(Within Day 1 after dosing)
- Rhodes Index of Nausea, Vomiting, and Retching (RINVR)(Within 24 hours following treatment.)
- Abdominal Pain, Visual Analog Scale (VAS) Score(Up to 24 hours post dose.)
- Intensity of Vomiting/Retching Attack(Within 24 hours post dose.)